OncoMatch/Clinical Trials/NCT06731894
Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
Is NCT06731894 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Cannabidiol and Dronabinol for breast carcinoma.
Treatment: Cannabidiol · Dronabinol — This phase II trials evaluates how well different types of phytocannabinoids (cannabidiol \[CBD\] versus tetrahydrocannabinol \[THC\] and CBD formulation \[THC:CBD\]) work to reduce chronic chemotherapy-induced peripheral neuropathy among breast and colon cancer survivors. Chemotherapy induced peripheral neuropathy is a set of symptoms that includes pain, tingling, numbness and motor weakness caused by certain types of chemotherapy treatment. Phytocannabinoids are compounds made by the cannabis plant, such as THC and CBD, that have been found to be an effective treatment for chronic pain. Phytocannabinoids may be effective in reducing chronic chemotherapy-induced peripheral neuropathy symptoms in patients treated for breast or colon cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Colorectal Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: taxane (paclitaxel, nab-paclitaxel, docetaxel)
previous chemotherapy treatment must have included a taxane (paclitaxel, nab-paclitaxel, or docetaxel)
Must have received: platinum-based chemotherapy (cisplatin, oxaliplatin, carboplatin)
previous chemotherapy treatment must have included a platinum (cisplatin, oxaliplatin, or carboplatin)
Cannot have received: taxane
Treatment with any neuropathic agent including taxane, platinum, vinca alkaloid, or bortezomib chemotherapy within the past 6 months
Cannot have received: platinum-based chemotherapy
Treatment with any neuropathic agent including taxane, platinum, vinca alkaloid, or bortezomib chemotherapy within the past 6 months
Cannot have received: vinca alkaloid
Treatment with any neuropathic agent including taxane, platinum, vinca alkaloid, or bortezomib chemotherapy within the past 6 months
Cannot have received: proteasome inhibitor (bortezomib)
Treatment with any neuropathic agent including taxane, platinum, vinca alkaloid, or bortezomib chemotherapy within the past 6 months
Lab requirements
Liver function
total bilirubin ≤ 1.5 x uln (unless has gilbert's disease); ast ≤ 3 x uln; alt ≤ 3 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
- City of Hope at Irvine Lennar · Irvine, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify